Nicholas A Butowski, MD
Neurology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 27 years
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb), 1999
Offices
1 location · UCSF Medical Group Business Services · 1,533 clinicians in this group
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Butowski’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A74692 · Current
Licensed to practise in California · since 2001 · expires 2028-09-30 · University of Illinois College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Neurology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$47,633
Medicare paid this office $47,633 for 82 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 73 | $24,495 | $124 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 73 | $6,295 | $27 |
| Advance care planning, first 30 minutes | 32 | $4,319 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,516 | $153 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 73 | $2,783 | $15 |
See all 7 services
| Long return visit (40+ min) | 73 | $24,495 | $124 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 73 | $6,295 | $27 |
| Advance care planning, first 30 minutes | 32 | $4,319 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,516 | $153 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 73 | $2,783 | $15 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 24 | $2,538 | $27 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,996 | $105 |
Who their Medicare patients are
82 Original Medicare patients in 2024. Average age 66 · Under 65 28% · Women 46% · Also on Medicaid 26% · Health risk score 1.42. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 50% · Depression 24% · Stroke 20% · Diabetes 17% · Cancer 15%.
The office billed $296,703, Medicare allowed $61,244 and paid $47,633; for 836 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 82 | 836 | 66 | 1.42 | $296,703 | $47,633 |
| 2023 | 72 | 381 | 68 | 1.31 | $207,297 | $29,151 |
| 2022 | 70 | 187 | 66 | 1.13 | $130,764 | $19,607 |
| 2021 | 50 | 126 | 66 | 1.37 | $81,593 | $14,062 |
| 2020 | 47 | 127 | 62 | 1.50 | $89,351 | $11,830 |
| 2019 | 41 | 96 | 63 | 1.44 | $73,902 | $9,539 |
| 2018 | 48 | 93 | 61 | 0.95 | $68,175 | $8,922 |
| 2017 | 42 | 89 | 60 | 1.39 | $60,557 | $8,273 |
| 2016 | 56 | 137 | 59 | 1.51 | $93,297 | $12,593 |
| 2015 | 62 | 124 | 61 | 1.42 | $82,434 | $11,930 |
| 2014 | 59 | 114 | 59 | 1.18 | $68,293 | $9,480 |
| 2013 | 56 | 108 | 59 | 1.19 | $56,748 | $7,807 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 59 | $19,730 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,335 | $156 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 36 | $1,822 | $27 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 14 | $797 | $27 |
2022: 3 services
| Long return visit (40+ min) | 57 | $14,524 | $115 |
| New patient visit (60+ min) | 12 | $1,950 | $162 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 17 | $537 | $27 |
2021: 1 service
| Long return visit (40+ min) | 34 | $9,836 | $129 |
2020: 1 service
| Long return visit (40+ min) | 35 | $7,659 | $93 |
2019: 1 service
| Long return visit (40+ min) | 35 | $6,523 | $91 |
2018: 1 service
| Long return visit (40+ min) | 42 | $7,442 | $92 |
2017: 1 service
| Long return visit (40+ min) | 35 | $6,905 | $92 |
2016: 2 services
| Long return visit (40+ min) | 48 | $10,055 | $92 |
| Return visit (30+ min) | 12 | $945 | $59 |
2015: 2 services
| Long return visit (40+ min) | 33 | $7,338 | $98 |
| Return visit (30+ min) | 20 | $1,965 | $65 |
2014: 2 services
| Long return visit (40+ min) | 20 | $4,011 | $93 |
| Return visit (30+ min) | 26 | $3,010 | $61 |
2013: 2 services
| Long return visit (40+ min) | 24 | $3,900 | $85 |
| Return visit (30+ min) | 26 | $2,013 | $59 |
Medicaid work
$7,941 in 2024
Medicaid paid $7,941 for 67 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 67 | $7,941 |
| 2024 | 67 | 1 | 15 | $7,941 |
| 2022 | 13 | 1 | 13 | $1,344 |
See the largest Medicaid services in earlier years
2022
| Long return visit (40+ min) | 13 | $1,344 |
Drugs they prescribed that Part D paid
$35,958
Pharmacies billed $35,958 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 89) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
83 generic and fewer than 11 brand-name prescriptions · $35,958 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Levetiracetam | 17 | $845 | $50 |
| Dexamethasone | 12 | $200 | $17 |
Year by year
| 2024 | 89 | 25 | 0% (0) | None | $35,958 |
| 2023 | 94 | 23 | 0% (0) | None | $7,475 |
| 2022 | 87 | 21 | 0% (0) | None | $5,552 |
| 2021 | 91 | 19 | None | 16% | $13,492 |
| 2020 | 95 | 21 | 0% (0) | 15% | $14,468 |
| 2019 | 112 | 24 | 0% (0) | None | $24,148 |
| 2018 | 114 | 21 | 0% (0) | None | $3,555 |
| 2017 | 94 | 19 | 0% (0) | None | $4,193 |
| 2016 | 150 | 26 | 0% (0) | None | $6,955 |
| 2015 | 91 | 18 | 0% (0) | None | $4,438 |
| 2014 | 81 | 16 | 0% (0) | None | $5,385 |
| 2013 | 86 | 16 | 0% (0) | 15% | $6,053 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Levetiracetam | 30 | $2,663 | $89 |
| Dexamethasone | 11 | $168 | $15 |
| Ondansetron | 11 | $148 | $13 |
| Lamotrigine | 12 | $142 | $12 |
| Lisinopril-Hydrochlorothiazide | 12 | $67 | $6 |
2022: 2 drugs
| Levetiracetam | 34 | $2,096 | $62 |
| Dexamethasone | 12 | $433 | $36 |
2021: 2 drugs
| Levetiracetam | 33 | $2,029 | $61 |
| Pregabalin | 13 | $169 | $13 |
2020: 3 drugs
| Gleostine | 11 | $9,298 | $845 |
| Levetiracetam | 36 | $1,317 | $37 |
| Gabapentin | 12 | $69 | $6 |
2019: 3 drugs
| Levetiracetam | 47 | $1,249 | $27 |
| Lamotrigine | 12 | $240 | $20 |
| Gabapentin | 14 | $65 | $5 |
2018: 1 drug
| Levetiracetam | 57 | $1,549 | $27 |
2017: 1 drug
| Levetiracetam | 53 | $1,607 | $30 |
2016: 4 drugs
| Levetiracetam | 67 | $1,529 | $23 |
| Carbamazepine | 11 | $685 | $62 |
| Dexamethasone | 14 | $411 | $29 |
| Lamotrigine | 21 | $141 | $7 |
2015: 1 drug
| Levetiracetam | 57 | $1,021 | $18 |
2014: 3 drugs
| Levetiracetam | 32 | $827 | $26 |
| Phenytoin Sodium Extended | 11 | $478 | $43 |
| Dexamethasone | 13 | $257 | $20 |
2013: 3 drugs
| Levetiracetam | 26 | $1,339 | $51 |
| Phenytoin Sodium Extended | 12 | $284 | $24 |
| Ondansetron | 14 | $252 | $18 |
Money from drug and device companies
$2,730 in 2025
| 2025 | 1 | 2 | $2,730 | $2,730 |
| 2024 | 2 | 3 | $2,610 | $2,655 |
| 2023 | 4 | 4 | $5,931 | $5,973 |
| 2022 | 2 | 2 | $2,321 | $2,321 |
| 2021 | 1 | 3 | $3,879 | $3,879 |
| 2020 | 1 | 1 | None | $67 |
| 2019 | 4 | 10 | $6,213 | $6,656 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ipsen Biopharmaceuticals | None | $2,730 | 2 payments
|
See all 2 published payments
| Ipsen Biopharmaceuticals | Consulting · 2025-07-09 | None | $1,365 |
| Ipsen Biopharmaceuticals | Consulting · 2025-06-09 | None | $1,365 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,655
| Ipsen Biopharmaceuticals | None | $2,610 | 2 payments
|
| Boston Scientific | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) | $45 | 1 payment
|
2023: $5,973
| Servier Pharmaceuticals | None | $4,080 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Vitrakvi | $1,199 | 1 payment
|
| Ipsen Biopharmaceuticals | None | $653 | 1 payment
|
| Boston Scientific | None | $42 | 1 payment
|
2022: $2,321
| Stemline Therapeutics | None | $1,920 | 1 payment
|
| Ipsen Biopharmaceuticals | None | $401 | 1 payment
|
2021: $3,879
| Ipsen Biopharmaceuticals | None | $3,879 | 3 payments
|
2020: $67
| Amgen | None | $67 | 1 payment
|
2019: $6,656
| Amgen | None | $3,546 | 6 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $2,510 | 2 payments
|
| Jazz Pharmaceuticals | None | $550 | 1 payment
|
| Ipsen Biopharmaceuticals | None | $50 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Ipsen Biopharmaceuticals, Inc · A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-Time Imaging With Gadolinium in Patients With Recurrent High Grade Glioma · 2020 | Their institution | $418,142 |
| Boston Scientific Corporation · Frontier · 2024 | Their institution | $365,330 |
| Boston Scientific Corporation · Frontier · 2025 | Their institution | $312,237 |
| Ipsen Biopharmaceuticals, Inc · A Phase I Study of Convection-Enhanced Delivery Ofliposomal-Irinotecan Using Real-Time Imaging With Gadoliniumin Patients With Recurrent High Grade Glioma · 2019 | Their institution | $178,828 |
| AbbVie, Inc. · 2019 | Their institution | $151,204 |
| Karyopharm Therapeutics Inc. · A Phase 1/2 Study of Selinexor in Combination With Soc Therapy for Newly Diagnosed Or Recurrent Glioblastoma · 2022 | Their institution | $117,728 |
| Sumitomo Pharma America, Inc. · A Phase 1 Study of Dsp-0390 in Patients With Recurrent High-Grade Glioma · 2024 | Their institution | $70,719 |
| E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l Registrational · 2020 | Their institution | $67,561 |
| Karyopharm Therapeutics Inc. · A Phase 1/2 Study of Selinexor in Combination With Soc Therapy for Newly Diagnosed Or Recurrent Glioblastoma · 2023 | Their institution | $59,125 |
| Karyopharm Therapeutics Inc. · A Phase 1/2 Study of Selinexor in Combination With Soc Therapy for Newly Diagnosed Or Recurrent Glioblastoma · 2024 | Their institution | $49,364 |
| Bayer HealthCare Pharmaceuticals Inc. · Stivarga · 2021 | Their institution | $45,610 |
| Bayer HealthCare Pharmaceuticals Inc. · Global Ma Regorafenib Pre-Clinical Rego and Nivo in Gbm Vineta · 2022 | Their institution | $45,610 |
| AstraZeneca UK Limited · A Modular Phase I/Iia, Open-Label, Multi-Centre Study To Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of Azd9574 As Monotherapy and in Combination With Anti-Cancer Agents in Patients With Advanced Solid Malignancies (Certis1) · 2023 | Their institution | $34,686 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2022 | Their institution | $32,913 |
| Karyopharm Therapeutics Inc. · A Phase 1/2 Study of Selinexor in Combination With Soc Therapy for Newly Diagnosed Or Recurrent Glioblastoma · 2021 | Their institution | $32,614 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt (Nivo Mono Rt) - A Randomized Phase 3 Open Label Study of Nivolumab Vs Temozolo Mide Each in Combination With Radiat Ion Therapy in Newly Diagnosed Adult Subjects With Unmethylated Mgmt (Tumor O-6 Methylguanine Dna Meth · 2023 | Their institution | $31,094 |
| Boston Scientific Corporation · Frontier · 2023 | Their institution | $29,812 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2021 | Their institution | $28,084 |
| E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l (Registrational) - A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and A Safety Study of Nivolumab Or Nivolumab in Combination With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (Gbm) · 2023 | Their institution | $26,641 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2024 | Their institution | $24,911 |
| AstraZeneca UK Limited · A Modular Phase I/Iia, Open-Label, Multi-Centre Study To Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of Azd9574 As Monotherapy and in Combination With Anti-Cancer Agents in Patients With Advanced Solid Malignancies (Certis1) · 2024 | Their institution | $24,609 |
| Ipsen Biopharmaceuticals, Inc · A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecanusing Real-Time Imaging With Gadolinium in Patients With Recurrent High Grade Glioma · 2021 | Their institution | $22,828 |
| Sumitomo Pharma America, Inc. · A Phase 1 Study of Dsp-0390 in Patients With Recurrent High-Grade Glioma · 2025 | Their institution | $22,455 |
| Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2022 | Their institution | $21,852 |
| JAZZ PHARMACEUTICALS INC. · Onc201 for the Treatment of Newly Diagnosed H3 K27m-Mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study · 2025 | Their institution | $20,921 |
| BeiGene, Ltd. · A Phase 1b/2 Study To Assess the Safety, Tolerability and Efficacy of Bgb-290 in Combination With Radiation Therapy (Rt) and/Or Temozolomide (Tmz) in Subjects With First-Line Or Recurrent/Refractory Glioblastoma · 2020 | Their institution | $19,538 |
| Kadmon Corporation LLC · A Phase 2 Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma · 2019 | Their institution | $18,446 |
| AstraZeneca UK Limited · A Modular Phase I/Iia, Open-Label, Multi-Centre Study To Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of Azd9574 As Monotherapy and in Combination With Anti-Cancer Agents in Patients With Advanced Solid Malignancies (Certis1) · 2025 | Their institution | $17,503 |
| Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2022 | Their institution | $14,570 |
| Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2021 | Their institution | $13,965 |
| Ipsen Biopharmaceuticals, Inc · A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-Time Imaging With Gadolinium in Patients With Recurrent High Grade Glioma · 2019 | Their institution | $10,556 |
| ABBVIE INC. · A Study of Abt-414 in Participants With Newly Diagnosed Glioblastoma (Gbm) With Epidermal Growth Factor Receptor (Egfr) Amplification · 2023 | Their institution | $9,724 |
| ABBVIE INC. · A Randomized, Placebo Controlled Phase 3 Study of Abt-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (Gbm) With Epidermal Growth Factor Receptor (Egfr) Amplification (Intellance1) · 2021 | Their institution | $9,518 |
| E.R. Squibb & Sons, L.L.C. · Ph III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2022 | Their institution | $9,230 |
| Ipsen Biopharmaceuticals, Inc · A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-Time Imaging With Gadolinium in Patients With Recurrent High Grade Glioma · 2022 | Their institution | $7,821 |
| AbbVie Inc. · 2020 | Their institution | $7,046 |
| BeiGene, Ltd. · A Phase 1b/2 Study To Assess the Safety, Tolerability and Efficacy of Bgb-290 in Combination With Radiation Therapy (Rt) and/Or Temozolomide (Tmz) in Subjects With First-Line Or Recurrent/Refractory Glioblastoma · 2021 | Their institution | $6,437 |
| Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2023 | Their institution | $5,985 |
| Arbor Pharmaceuticals, Inc. · Vigilant Observation of Gliadel Wafer Implant Registry (Vigilant) · 2020 | This clinician | $5,768 |
| E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l Registrational · 2019 | Their institution | $5,232 |
| Arbor Pharmaceuticals, Inc. · Vigilant Observation of Gliadel Wafer Implant Registry Vigilant · 2019 | This clinician | $3,591 |
| Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2020 | Their institution | $1,875 |
| E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l (Registrational) - A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and A Safety Study of Nivolumab Or Nivolumab in Combination With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (Gbm) · 2024 | Their institution | $1,163 |
| E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l Registrational · 2021 | Their institution | $625 |
| Sumitomo Pharma America, Inc. · A Phase 1 Study of Dsp-0390 in Patients With Recurrent High-Grade Glioma · 2023 | Their institution | $396 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1184681009
- Licence
- CA A74692California A74692: Current · expires 2028-09-30
- Trained
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb), 1999 · 27 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A746920
- Taxonomy
- Federal specialty code 207T00000X (207T00000X)
- Mailing address
- 1635 Divisadero St, Ste 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-04-26
- NPI last updated
- 2008-07-23
This is when the NPI record was last certified, not a medical board exam.